Position in PTGX
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$62,713
+$24,633 QoQ
Shares Held
595
+36.5% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Salomon & Ludwin, LLC holds $831,895 across 38 Biotechnology names. PTGX ranks #2 (7.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PTCT |
Ptc Therapeutics, Inc.
|
969 | $66,017 | |
| 2 | PTGX |
Protagonist Therapeutics, Inc
This page
|
595 | $62,713 | |
| 3 | TGTX |
Tg Therapeutics, Inc.
|
1,699 | $56,440 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
121 | $54,031 | |
| 5 | KRYS |
Krystal Biotech, Inc.
|
201 | $51,922 | |
| 6 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
1,866 | $46,202 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
58 | $44,813 | |
| 8 | ACAD |
Acadia Pharmaceuticals Inc
|
1,926 | $42,872 |
All Filings in PTGX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $62,713 | 595 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $38,080 | 436 | Shares | Sole | 2026-01-28 | |
| 2025-09-30 | $29,362 | 442 | Shares | Sole | 2025-10-21 | |
| No filing history on record for this holder in this stock. | ||||||